Clinical trials: Advanced Malignancies
Metastases, Neoplasm, Carcinoma, Non-small Cell Lung
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.
- Conditions
- Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
- Trial name
- NCT01115803
- Testing
- LY2584702, Erlotinib, Everolimus
- Where
- 3 sites in United States, France
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer
This phase II trial studies how well temsirolimus works in treating patients with breast cancer that has spread to other places in the body.
- Conditions
- Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7
- Trial name
- NCT00376688
- Testing
- Laboratory Biomarker Analysis, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
This Phase II, double-blind, randomized, placebo-controlled multicenter study will investigate the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or atezolizumab-placebo in participants with…
- Trial name
- KATE2 (NCT02924883)
- Testing
- Atezolizumab, Trastuzumab emtansine
- Where
- 68 sites in United States, Australia and 7 more
- Volunteers
- 202 people
- Sponsor
- Hoffmann-La Roche
Skin Squamous Cell Carcinoma, Metastatic Skin Cancer
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
This phase II trial studies how well avelumab with or without cetuximab work in treating patients with skin squamous cell cancer that has spread to other places in the body.
- Trial name
- NCT03944941
- Testing
- Avelumab, Cetuximab
- Where
- 428 sites in United States
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
The purpose of this study is to compare the efficacy and tolerability of Faslodex (fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor positive advanced breast cancer.
- Trial name
- FIRST (NCT00274469)
- Testing
- fulvestrant, anastrozole
- Where
- 41 sites in United States, Brazil and 7 more
- Volunteers
- 205 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC…
- Trial name
- ATALANTE-1 (NCT02654587)
- Testing
- OSE2101, Docetaxel, Pemetrexed
- Where
- 78 sites in United States, Czechia and 8 more
- Volunteers
- 219 people
- Sponsor
- OSE Immunotherapeutics
Prostate Cancer
Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer
Assess the efficacy and safety of Triptorelin pamoate 3M formulation (11.25mg) when administered by subcutaneous route.
- Trial name
- DKP 3M SC (NCT01715129)
- Testing
- Triptorelin Pamoate 11.25mg
- Where
- 12 sites in Bulgaria, France and 3 more
- Volunteers
- 126 people
- Sponsor
- Ipsen
Breast Cancer, Ovarian Cancer
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
This was a Phase 1, open-label, nonrandomized, multicenter study of durvalumab and tremelimumab in subjects with advanced cancers who were not eligible for, declined, or failed standard treatment.
- Conditions
- Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer
- Trial name
- NCT01975831
- Testing
- Durvalumab, Tremelimumab
- Where
- 6 sites in United States
- Volunteers
- 104 people
- Sponsor
- Ludwig Institute for Cancer Research
Breast Cancer
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer
This randomized, open-label, two-arm, multi-center, Phase II study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab plus an aromatase inhibitor (AI) in first-line participants with HER2-positive…
- Trial name
- PERTAIN (NCT01491737)
- Testing
- Pertuzumab, Trastuzumab, Aromatase Inhibitor
- Where
- 82 sites in United States, Brazil and 6 more
- Volunteers
- 258 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Mantle Cell Lymphoma
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells, either…
- Conditions
- Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, SLL
- Trial name
- VCR (NCT00980395)
- Testing
- rituximab, bortezomib, cladribine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Arizona
Melanoma, Carcinoma, Non-Small- Cell Lung
A Study of SEA-CD40 Given With Other Drugs in Cancers
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial.
- Trial name
- NCT04993677
- Testing
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 77 people
- Sponsor
- Seagen Inc.
Advanced Pancreatic Cancer
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
To compare, in patients with advanced pancreatic cancer, the effects of IMM-101 in combination with gemcitabine to gemcitabine alone on safety and tolerability (including QoL), clinical signs and symptoms of disease, selected…
- Trial name
- NCT01303172
- Testing
- IMM-101, Gemcitabine
- Where
- 21 sites in Cyprus, Ireland and 3 more
- Volunteers
- 110 people
- Sponsor
- Immodulon Therapeutics Ltd
Colorectal Cancer
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
This is a multi-institutional, single arm, open-label, phase II study, including a safety run-in cohort. No randomization or blinding involved.
- Trial name
- NCT02375672
- Testing
- Pembrolizumab, mFOLFOX6
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Hoosier Cancer Research Network
Head and Neck Squamous Cell Carcinoma
Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
This is a Phase II trial of definitive chemoradiotherapy (CTRT) given with the protease inhibitor,Nelfinavir (NFV), in patients with locally advanced head and neck.
- Trial name
- NCT02207439
- Testing
- Nelfinavir (Viracept®) 1250 mg, Chemoradiation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non Small Cell Lung Cancer (Stage III)
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
- Trial name
- LAURA (NCT03521154)
- Testing
- Osimertinib 80mg/40mg
- Where
- 118 sites in United States, Argentina and 15 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Metastatic Cancer
A Study of LY3007113 in Participants With Advanced Cancer
This study evaluates the safety and tolerability of different doses of an experimental treatment in participants with advanced cancer.
- Trial name
- NCT01463631
- Testing
- LY3007113
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Eli Lilly and Company
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)
This phase II MATCH treatment trial tests how well palbociclib (PD-0332991) works in treating patients with cancer that has certain genetic changes. Palbociclib (PD-0332991) is in a class of medications called kinase inhibitors.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390839
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Urothelial Carcinoma
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma
- Trial name
- ATLAS (NCT03397394)
- Testing
- Rucaparib
- Where
- 64 sites in United States, France and 4 more
- Volunteers
- 97 people
- Sponsor
- pharmaand GmbH
Advanced Haematological Malignancies
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer
This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participants dose ramp up.
- Trial name
- NCT04630756
- Testing
- AZD4573, Acalabrutinib
- Where
- 17 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
ER Reactivation Therapy for Breast Cancer
Before anti-estrogens such as tamoxifen were developed to treat estrogen receptor (ER)-positive breast cancer, high-dose estrogen therapies were used.
- Trial name
- POLLY (NCT02188745)
- Testing
- 17B-estradiol, Letrozole, Anastrozole
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.